Table 1. Correlation of CXCL12-expression in tumour cells with clinicopathological patient characteristics.
| Gastric carcinoma | Patients | CXCL12 immunoreactivity | ||
| 0 | 1 | P | ||
| Total | 347 | |||
| Age, years | ||||
| ≤65, n (%) | 138 | 20 (14) | 118 (86) | ns (p = 0.525) |
| >65, n (%) | 153 | 27 (18) | 126 (82) | |
| Gender | ||||
| men, n (%) | 187 | 32 (17) | 155 (83) | ns (p = 0.621) |
| women, n (%) | 103 | 15 (15) | 88 (85) | |
| T category | ||||
| pT1/pT2a, n (%) | 48 | 8 (17) | 40 (83) | ns (p = 1.0) |
| pT2b/pT3/pT4, n (%) | 241 | 39 (16) | 202 (84) | |
| pT1/pT2, n (%) | 151 | 24 (16) | 127 (84) | ns (p = 1.0) |
| pT3/pT4, n (%) | 140 | 23 (16) | 117 (84) | |
| Lymph nodes | ||||
| no metastases (%) | 74 | 8 (11) | 66 (89) | ns (p = 0.20) |
| Metastases (%) | 215 | 39 (18) | 176 (82) | |
| pN0, n (%) | 74 | 8 (11) | 66 (89) | ns (p = 0.22) |
| pN1, n (%) | 103 | 16 (16) | 87 (84) | |
| pN2, n (%) | 78 | 14 (18) | 64 (82) | |
| pN3, n (%) | 34 | 9 (26) | 25 (74) | |
| M category | ||||
| pM0, n (%) | 257 | 37 (14) | 220 (86) | p = 0.043 |
| pM1, n (%) | 34 | 10 (29) | 24 (71) | |
| Grade | ||||
| G1/G2, n (%) | 77 | 5 (6) | 72 (94) | p = 0.0064 |
| G3/G4, n (%) | 214 | 42 (20) | 172 (80) | |
| UICC | ||||
| I, n (%) | 57 | 10 (18) | 47 (82) | ns (p = 0.262) |
| II, n (%) | 73 | 7 (10) | 66 (90) | |
| III, n (%) | 95 | 14 (15) | 79 (85) | |
| IV, n (%) | 68 | 16 (24) | 52 (76) | |